{"id":"https://openalex.org/keywords/fc-engineering","display_name":"Fc engineering","description":"Modification of an antibody\u2019s fragment crystallizable (Fc) region to alter properties such as effector activity, receptor binding, or serum half-life.","display_name_alternatives":["antibody Fc engineering","Fc region engineering","engineering of the Fc region","fragment crystallizable region engineering"],"ids":{"openalex":"https://openalex.org/keywords/fc-engineering","wikidata":null},"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6417,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6417,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0701,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"works_count":514,"cited_by_count":12261,"works_api_url":"https://api.openalex.org/works?filter=keywords.id:keywords/fc-engineering","updated_date":"2026-11-16T04:05:30","created_date":"2026-09-30T00:00:00"}
